A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.

Moreover, the PETACC 3 study reported a 3-year DFS advantage for an irinotecan/5-FU/FA regimen as well, although this study did not reach statistical significance, most probably because of an to an imbalance in risk factors in both treatment arms ( van Cutsem et al , 2005 ).

also in 111,027 other papers